Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Next Previous
Trial Profile

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA 402 (Primary)
  • Indications Gynaecological cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Skin cancer; Solid tumours; Synovial sarcoma; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Immatics N.V.

Most Recent Events

  • 12 May 2026 According to an Immatics media release, the Company is in the process of opening additional Phase 1b cohorts in mid-2026 across both earlier and later treatment lines.
  • 21 Apr 2026 According to an Immatics media release, data from the trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA.
  • 05 Mar 2026 According to an Immatics N.V. media release, IMA402 monotherapy and combination with immune checkpoint inhibitor are planned for 2H 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top